Nobias Therapeutics Announces Acceptance Of Late-Breaking Abstract

Nobias Therapeutics, a biotechnology company pioneering AI-based deep phenotyping techniques to discover advanced therapeutics, today announced new results.

From a Phase 2 clinical trial of NB-001 (fasoracetam) for the treatment of the neuropsychiatric symptoms associated with 22q11.2 deletion syndrome (“22q11DS”) in children have been selected for a poster presentation at the 52nd Child Neurology Society (CNS) Annual Meeting.

MOUNTAIN VIEW, Calif. and PHILADELPHIA, Sept. 20, 2023 /PRNewswire-PRWeb/ — Nobias Therapeutics, a biotechnology company pioneering AI-based deep phenotyping techniques to discover advanced therapeutics, today announced that new results from a Phase 2 clinical trial of NB-001 (fasoracetam) for the treatment of the neuropsychiatric symptoms associated with 22q11.2 deletion syndrome (“22q11DS”) in children have been selected for a poster presentation at the 52nd Child Neurology Society (CNS) Annual Meeting, to be held October 4-7, 2023, in Vancouver, BC.

Read the full article here 

Previous

Next